Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

19.25
Delayed Data
As of Feb 27
 +0.27 / +1.42%
Today’s Change
15.15
Today|||52-Week Range
39.74
+15.48%
Year-to-Date
Bullish and Bearish Reversals in the Market
Feb 27 / TheStreet.com - Paid Partner Content
Here's Why Invitae Stock Jumped as Much as 16.3% This Morning
Feb 14 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close18.98
Today’s open19.21
Day’s range18.69 - 19.30
Volume1,606,453
Average volume (3 months)1,556,408
Market cap$1.3B
Dividend yield--
Data as of 02/27/2017

Growth & Valuation

Earnings growth (last year)+58.33%
Earnings growth (this year)-38.83%
Earnings growth (next 5 years)-4.30%
Revenue growth (last year)+4.25%
P/E ratio22.4
Price/Sales2.98
Price/Book1.78

Competitors

 Today’s
change
Today’s
% change
AAAPAdvanced Accelerator...+0.30+0.81%
QDELQuidel Corp+0.74+3.50%
--Quidel Corp-0.20-1.01%
ALRPRBAlere Inc-0.02-0.01%
Data as of 02/27/2017

Financials

Next reporting dateMay 9, 2017
EPS forecast (this quarter)$0.24
Annual revenue (last year)$753.8M
Annual profit (last year)$125.3M
Net profit margin16.62%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts


Search for Jobs